We designed T cells to constitutively express SNIPR that targets EGFRvIII and to conditionally express CAR that targets the distinct antigen IL13 receptor α-2, analogous to our previous approach to targeting glioblastoma with cytotoxic CD8 T cells (12). The gene discussed is CD8A; the disease is glioblastoma.